Session » Vasculitis – ANCA-Associated Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1610

Anti-neutrophil Cytoplasmic Antibodies Associated Interstitial Pneumonia: A New Clinical Entity?

10:30AM-12:30PM: Abstract Number: 1603

Antineutrophil Cytoplasmic Autoantibody Levels in Patients in the Avacopan Phase 3 Trial

10:30AM-12:30PM: Abstract Number: 1597

Baseline Glucocorticoid-Related Toxicity in Newly-Diagnosed and Relapsing ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 1601

Changing Spectrum of Systemic Therapies for Eosinophilic Granulomatosis with Polyangiitis from 2006-2023

10:30AM-12:30PM: Abstract Number: 1609

Characteristics of a Cohort of Patients with Interstitial Lung Disease and ANCA Positivity in a University Hospital

10:30AM-12:30PM: Abstract Number: 1605

Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1602

Complications in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Patients: A Nationwide Analysis

10:30AM-12:30PM: Abstract Number: 1606

Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data

10:30AM-12:30PM: Abstract Number: 1596

Efficacy of Eosinophil-Targeting Therapies According to Disease Severity in Patients with Eosinophilic Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1593

Efficacy of Increasing the Dose of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1599

Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis with Poor-Prognosis Factors: A Target Trial Emulation Study

10:30AM-12:30PM: Abstract Number: 1600

Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis Without Poor-Prognosis Factors: A Target Trial Emulation Study

10:30AM-12:30PM: Abstract Number: 1611

Impact of Mepolizumab on Patient-reported Outcomes in Eosinophilic Granulomatosis with Polyangiitis by Using the ANCA-associated Vasculitis Patient-reported Outcomes (AAV-PRO) Questionnaire: A European Multicentre Prospective Study

10:30AM-12:30PM: Abstract Number: 1608

Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes

10:30AM-12:30PM: Abstract Number: 1607

Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

10:30AM-12:30PM: Abstract Number: 1592

Overlapping Forms of Eosinophilic Granulomatosis with Polyangiitis and Granulomatosis with Polyangiitis: Presentation, Management and Outcomes

10:30AM-12:30PM: Abstract Number: 1598

Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling

10:30AM-12:30PM: Abstract Number: 1594

Response to Mepolizumab Therapy in a Single-center Cohort of Eosinophilic Granulomatosis with Polyangiitis Patients: Characterization of Cytokine/Chemokine Pattern and Phenotypic Stratification

10:30AM-12:30PM: Abstract Number: 1595

Tezepelumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study

10:30AM-12:30PM: Abstract Number: 1604

Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis

« View all sessions from this meeting